VOR

VOR remains in a Stage 2 advancing structure with active Momentum Breakout and higher highs & lows confirming bullish continuation, but given the speculative strategy and price extended above rising EMAs, execution is deferred until a pullback into the 24.1–25.1 support zone for a clear entry.

• ↑Advancing telitacicept in global Phase 3 trials for myasthenia gravis and Sjögren’s
• ↑$491.5 M capital reserve supports late‐stage clinical development
• ↓Negative earnings yield and poor profitability raise sustainability concerns